Organization and Description of Business (Details Narrative) |
3 Months Ended | 10 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 05, 2024
USD ($)
$ / shares
|
Feb. 23, 2024 |
Feb. 14, 2024
shares
|
Feb. 13, 2024
shares
|
Nov. 13, 2023
USD ($)
|
Feb. 21, 2023
USD ($)
$ / shares
shares
|
Mar. 31, 2024
USD ($)
$ / shares
shares
|
Mar. 31, 2023
USD ($)
shares
|
Dec. 14, 2024 |
Dec. 31, 2023
USD ($)
$ / shares
shares
|
Mar. 04, 2024
$ / shares
|
Feb. 28, 2023
$ / shares
shares
|
|
| Conversion price of preferred shares | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||
| Common stock, par value | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||
| Reverse Stock Split | 1-for-30 | 1-for-30 | ||||||||||
| Stock Issued During Period, Shares, Reverse Stock Splits | shares | 16,666,666 | 500,000,000 | ||||||||||
| Common stock, shares authorized | shares | 66,666,666 | 550,000,000 | 16,666,666 | 16,666,666 | ||||||||
| Issuance of preferred shares | ||||||||||||
| Preferred stock dividends | $ 1,201,867 | 158,333 | ||||||||||
| Derivative liability fair value | $ 3,149,800 | 0 | ||||||||||
| Stock issuance costs | 314,311 | |||||||||||
| Fair value of the warrants | 10,623,000 | |||||||||||
| Change in fair value of Derivatives Liabilities | $ 61,000 | (120,700) | ||||||||||
| Probability of default | 1.05 | |||||||||||
| Fair value of the warrants | 10,623,000 | |||||||||||
| Issuance of warrants | 762,834 | |||||||||||
| Fair value adjustment of warrants | 7,094,000 | (1,175,000) | ||||||||||
| Fair value of the warrants | 7,961,000 | $ 867,000 | ||||||||||
| Employment agreement description | Effective November 13, 2023, the Company entered into an amendment to the employment agreement of Dr. Chris Chapman, its President and Chief Medical Officer, providing for Dr. Chapman’s annual base salary to be adjusted from five hundred thousand dollars ($500,000) (the “Full Base Salary”) to two hundred fifty thousand dollars ($250,000) in cash per annum, until payment of his Full Base Salary would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion. The amendment further provides that the remaining $250,000 of base salary per annum (the “Deferral Amount”) shall be deferred until payment of the Deferral Amount would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion, at which time the Deferral Amount may be paid, at Dr. Chapman’s election, in shares of Common Stock or in cash. As of March 31, 2024 and December 31, 2023, the Company had recognized a salary deferral of $86,538 and $28,846, respectively, which is included in Deferred Compensation Payable on the Condensed Consolidated Balance Sheets. | |||||||||||
| Implementation of directors agreement description | In connection with an overall reduction in compensation paid to the Company’s directors implemented in November 2023, effective November 13, 2023, the Company entered into an amendment to the employment agreement of Christopher C. Schreiber, a Director and the Company’s former Executive Chairman, providing for Mr. Schreiber’s annual fee to be adjusted from three hundred thousand dollars ($300,000) (the “Full Fee”) to sixty thousand dollars ($60,000) in cash per annum, until payment of his Full Fee would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion. The amendment further provides that the remaining $240,000 of the fees per annum (the “Fee Deferral Amount”) shall be deferred until payment of the Fee Deferral Amount would no longer jeopardize the Company’s ability to continue as a going concern, as determined by the Company in its sole discretion, at which time the Fee Deferral Amount may be paid, at Mr. Schreiber’s election, in shares of Common Stock or in cash. The amendment also clarified that Mr. Schreiber’s title is “Director.” As of March 31, 2024 and December 31, 2023, the Company had recognized a salary deferral of $83,077 and $27,692, respectively, which is included in Deferred Compensation Payable on the Condensed Consolidated Balance Sheets. | |||||||||||
| Deferred Compensation Payable [Member] | ||||||||||||
| Board fee deferral | 110,000 | 44,000 | ||||||||||
| Other Operating Income (Expense) [Member] | ||||||||||||
| Change in fair value of Derivatives Liabilities | $ 61,000 | $ 120,700 | ||||||||||
| Fair value of common stock on valuation date | $ / shares | $ 2.39 | |||||||||||
| Fair value adjustment of warrants | $ 7,094,000 | $ 1,750,000 | ||||||||||
| Common Stock [Member] | ||||||||||||
| Reverse Stock Split | one-for-thirty | |||||||||||
| Stock Issued During Period, Shares, Reverse Stock Splits | shares | 65,960 | |||||||||||
| Issuance of preferred shares | ||||||||||||
| Exercise price | $ / shares | $ 2.39 | $ 7.77 | ||||||||||
| Preferred Stock [Member] | ||||||||||||
| Issuance of preferred shares | 14,087,111 | |||||||||||
| Derivative liability fair value | 3,149,800 | |||||||||||
| Warrant [Member] | ||||||||||||
| Warrants term | 3 years 10 months 24 days | 4 years 1 month 24 days | ||||||||||
| Measurement Input, Expected Dividend Rate [Member] | ||||||||||||
| Estimated dividend rate | 10.00 | 10.00 | ||||||||||
| Estimated Equity volatility | 95.00% | |||||||||||
| Fair value assumptions risk free interest rate | 6.20% | |||||||||||
| Estimated dividend rate | 15.00 | |||||||||||
| Measurement Input, Exercise Price [Member] | Common Stock [Member] | ||||||||||||
| Exercise price | $ / shares | $ 1.90 | |||||||||||
| Measurement Input, Option Volatility [Member] | ||||||||||||
| Estimated dividend rate | 120.00 | |||||||||||
| Stock price per share | 110.00 | 120.00 | ||||||||||
| Measurement Input, Price Volatility [Member] | ||||||||||||
| Estimated dividend rate | 190.00 | |||||||||||
| Measurement Input, Maturity [Member] | ||||||||||||
| Time of maturity | 1 year 4 months 6 days | |||||||||||
| Measurement Input, Maturity [Member] | Other Operating Income (Expense) [Member] | ||||||||||||
| Time of maturity | 3 months | |||||||||||
| Measurement Input, Discount Rate [Member] | ||||||||||||
| Estimated dividend rate | 6.08 | |||||||||||
| Measurement Input, Lapse Rate [Member] | ||||||||||||
| Estimated dividend rate | 15.00 | |||||||||||
| Measurement Input, Default Rate [Member] | ||||||||||||
| Estimated dividend rate | 0.05 | |||||||||||
| Measurement Input Volume Volatility [Member] | ||||||||||||
| Estimated traded volume volatility | 175.00 | |||||||||||
| Measurement Input, Expected Dividend Payment [Member] | ||||||||||||
| Stock price per share | 0 | 0 | ||||||||||
| Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||
| Stock price per share | 4.31 | 3.91 | ||||||||||
| Series F Convertible Preferred Stock [Member] | ||||||||||||
| Conversion price per share | $ / shares | $ 2.255 | |||||||||||
| Conversion of stock, description | (i) the Conversion Price then in effect and (ii) the greater of (A) 80% of the average of the three lowest closing prices of the Company’s Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) a “Floor Price” of $6.60 (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Stock Market. | If on any day after the issuance of the shares of Series F Preferred Stock the closing price of the Common Stock has exceeded $202.95 (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) for 20 consecutive trading days and the daily dollar trading volume of the Common Stock has exceeded $3,000,000 per trading day during the same period and certain equity conditions described in the Series F Certificate of Designation are satisfied (the “Mandatory Conversion Date”), we shall deliver written notice of the Mandatory Conversion (as defined below) to all holders on the Mandatory Conversion Date and, on such Mandatory Conversion Date, we shall convert all of each holder’s shares of Series F Preferred Stock into Conversion Shares at the then effective Conversion Price (the “Mandatory Conversion”). If any of the Equity Conditions shall cease to be satisfied at any time on or after the Mandatory Conversion Date through and including the actual delivery of all of the Conversion Shares to the holders, the Mandatory Conversion shall be deemed withdrawn and void ab initio | ||||||||||
| Preferred shares dividend rate | 10.00% | 10.00% | ||||||||||
| Series F Convertible Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||
| Issuance of preferred shares | $ 912,889 | |||||||||||
| Series F Convertible Preferred Stock [Member] | Minimum [Member] | ||||||||||||
| Conversion price per share | $ / shares | $ 60.21 | $ 60.21 | ||||||||||
| Series F Convertible Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||
| Preferred shares dividend rate | 15.00% | |||||||||||
| Series F Convertible Preferred Stock [Member] | Measurement Input, Default Rate [Member] | ||||||||||||
| Preferred shares dividend rate | 15.00% | |||||||||||
| Series F Convertible Preferred Stock [Member] | Subsequent Event [Member] | ||||||||||||
| Share issued price, per share | $ / shares | $ 202.95 | |||||||||||
| Issuance of preferred shares | $ 3,000,000 | |||||||||||
| Series F Convertible Preferred Stock [Member] | Subsequent Event [Member] | Minimum [Member] | ||||||||||||
| Conversion price per share | $ / shares | $ 60.21 | |||||||||||
| Director [Member] | ||||||||||||
| Deferral excess payment | $ 156,000 | |||||||||||
| Director [Member] | Minimum [Member] | ||||||||||||
| Director fees | 60,000 | |||||||||||
| Director [Member] | Maximum [Member] | ||||||||||||
| Director fees | 216,000 | |||||||||||
| Eagle Uzonwanne [Member] | ||||||||||||
| Deferral excess payment | 36,000 | |||||||||||
| Eagle Uzonwanne [Member] | Minimum [Member] | ||||||||||||
| Director fees | 60,000 | |||||||||||
| Eagle Uzonwanne [Member] | Maximum [Member] | ||||||||||||
| Director fees | $ 96,000 | |||||||||||
| Securities Purchase Agreement [Member] | ||||||||||||
| Fair value of the warrants | $ 10,623,000 | |||||||||||
| Securities Purchase Agreement [Member] | Warrant [Member] | ||||||||||||
| Warrants term | 5 years | |||||||||||
| Securities Purchase Agreement [Member] | Measurement Input, Option Volatility [Member] | ||||||||||||
| Stock price per share | 125.00 | |||||||||||
| Securities Purchase Agreement [Member] | Measurement Input, Expected Dividend Payment [Member] | ||||||||||||
| Stock price per share | 0 | |||||||||||
| Securities Purchase Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||
| Stock price per share | 4.09 | |||||||||||
| Securities Purchase Agreement [Member] | Investors [Member] | ||||||||||||
| Conversion price of preferred shares | $ / shares | $ 3.18 | |||||||||||
| Sale of Stock, Number of Shares Issued in Transaction | shares | 15,000 | |||||||||||
| Sale of Stock, Consideration Received on Transaction | $ 1,000 | |||||||||||
| Convertible Preferred Stock, Shares Issued upon Conversion | shares | 6,651,885 | |||||||||||
| Warrant exercise price | $ / shares | $ 2.255 | $ 3.18 | ||||||||||
| Proceeds from Issuance of Warrants | $ 6,651,885 | |||||||||||
| Warrant, Exercise Price, Decrease | $ / shares | $ 3.18 | |||||||||||
| Warrants to purchase common stock | shares | 4,716,904 | 4,716,904 | ||||||||||
| Warrants term | 5 years | 5 years | ||||||||||
| Securities Purchase Agreement [Member] | Investors [Member] | Common Stock [Member] | ||||||||||||
| Warrants to purchase common stock | shares | 4,716,904 | |||||||||||